Cytokinetics, IncorporatedCYTKNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +912.38% | +89.10% | +26714.86% | +318.14% | +4.89% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +19.19% | +16.26% | +9.35% | +1.95% | +3.34% |
| Weighted Average Shares Diluted Growth | +19.19% | +16.26% | +9.35% | +1.95% | +3.69% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1197.74% | +141.25% | +0.00% | +640.98% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +70.04% | +56.43% | -19.57% | +0.03% | +1.63% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +4.35% | +4.79% | +8.59% | +51.57% | +62.84% |
| R&D Expense Growth | +10.18% | +22.40% | +41.40% | +17.28% | +8.45% |
| SG&A Expenses Growth | +41.31% | +26.09% | +29.31% | +22.60% | +47.14% |